Qkine

Executive Summary

Qkine is a UK-based biotechnology company founded in 2017 that specializes in the design and manufacture of high-purity, bioactive recombinant cytokine proteins and growth factors. Its products target demanding applications in stem cell culture, organoid research, and regenerative medicine, offering an animal-free manufacturing platform that enhances scientific reproducibility. The company has carved a niche in the growing cell therapy and regenerative medicine sectors, where consistent, high-quality growth factors are critical for both research and clinical translation. By addressing the reproducibility crisis in life sciences, Qkine positions itself as a key enabler of advanced cell-based therapies and organoid models, with potential to become a preferred supplier for both academic and industrial customers. Its focus on rigorous quality control and animal-free production aligns with the increasing regulatory and ethical demands for safer, more consistent biological reagents. Qkine's technology platform could also expand into other high-growth areas such as cultured meat or bioprocessing, diversifying its revenue streams and market opportunity.

Upcoming Catalysts (preview)

• Q2 2026Series A Funding Round60% success
• Q4 2026Strategic Partnership with Major Pharma or CRO50% success
• Q1 2027Launch of Growth Factors for iPSC-Derived Cell Therapies70% success